Norbert Zilka is the director of Institute of Neuroimmunology, SAS and CSO of the biotech company Axon Neuroscience. He is the founder of the first Slovak brain bank. Norbert holds a PhD in Immunology from the Slovak Academy of Sciences (SAS). His main scientific focus is on human neurodegenerative disorders such as Alzheimer’s disease, ALS and FTD. He was actively involved in the preclinical and clinical development of the first-in-man, first-in-kind tau vaccine against Alzheimer’s disease and tau diagnostic assay for AD. He took part of several JPND projects such as BIOMARKAPD (2012-2015), REfrAME (2016-2019) and

ADDITION (2019-2023).

Contributions:

• recruitment of participants
• metabolomic analysis